← Back to headlines
ImmunityBio Reports 700% Revenue Surge Driven by ANKTIVA Adoption
ImmunityBio (IBRX) announced a significant 700% increase in revenue, primarily attributed to the rapid adoption of its product, ANKTIVA.
25 Feb, 11:19 — 25 Feb, 11:19
Sources
Showing 1 of 1 sources
